ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, recent findings that BCR-ABL can function independent of its tyrosine kinase activity9, 10 and that survival of CML stem cells is independent of BCR-ABL tyrosine kinase activity11 strongly encourage new strategies of targeting BCR-ABL (e.g., targeting BCR-ABL’s scaffolding ability or its DNA-binding ability, inducing degradation of BCR-ABL) to be used for improved therapeutic outcomes2, 3, 12.